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Abstract In the pathogenesis of multiple sclerosis (MS),
oligodendrocytes and its myelin sheaths are thought to be
the primary target of destruction. The mechanism leading to
oligodendrocyte injury and demyelination is still elusive.
Oligodendrocytes are maintaining up to 50 internodes of
myelin, which is an extraordinary metabolic demand. This
makes them one of the most vulnerable cell types in the
central nervous system (CNS), and even small insults can
lead to oligodendrocyte impairment, demyelination, and
axonal dysfunction. For this reason, oligodendrocytes are
viewed as more or less the “lame ducks” of the CNS who
can easily become victims. However, recent data demon-
strate that this perception possibly needs to be revised. The
latest data suggest that oligodendrocytes may also act as
“fierce creatures,” influencing the surrounding cells in
many ways to preserve its own, as well as their function,
allowing sustained functionality of the CNS upon an attack.
In this review, the concept of “reactive or activated
oligodendrocyte” is introduced, describing alterations in
oligodendrocytes which are either protective mechanisms
allowing survival in otherwise lethal environment or
influence and possibly modulate the ongoing inflammation.
Although “harnessed”, oligodendrocytes might actively
modulate and shape their environment and be part of the
immune privilege of the brain.
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Introduction
Multiple sclerosis (MS) is an inflammatory, demyelinating
disease of the central nervous system (CNS). The patho-
logical hallmark of the disease is the inflammatory plaque.
Studies of its histopathology have revealed a wide
heterogeneity at the cellular and molecular levels, which
might partially reflect the diversity of the clinical disease
course (Lucchinetti et al. 2000). There are several hypoth-
eses to explain the immunological injury in MS. In the most
prominent and most widely accepted hypothesis, MS is
driven by a T cell-mediated immune response leading to
secondary macrophage and microglia activation and demy-
elination (Compston et al. 2006). In a majority of MS cases,
this immune response is further accompanied by antibodies
or complement deposition (Lucchinetti et al. 2000). Other
hypotheses implicate a viral pathogenesis to be the origin of
MS (Kennedy and Steiner 1994) or intrinsic oligodendro-
cyte damage leading to subsequent MS disease (Lucchinetti
et al. 2000).
One of the major features of an inflammatory plaque is
demyelination and the loss of oligodendrocytes (Ozawa et
al. 1994). Because of the fact that oligodendrocytes are
highly specialized and have a high metabolic demand
maintaining many myelin sheaths, oligodendrocytes are one
of the most vulnerable cells in the CNS. There are many
ways which lead to oligodendrocyte impairment and injury
(for review see Ludwin 1997; Raine 1997; Merrill and
Scolding 1999). Still, oligodendrocyte apoptosis and loss is
not the major feature in MS, implicating that the major
target of the destructive process is the myelin sheath
(Ozawa et al. 1994). In particular cases, however, oligo-
dendrocyte apoptosis might be a primary cause (Lucchinetti
et al. 2000; Barnett and Prineas 2004). Studies from animal
models showed that T cell infiltration and subsequent
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inflammation in the CNS per se does not necessarily lead to
extensive demyelination (for review see Gold et al. 2000;
Gold et al. 2006). Furthermore, oligodendrocytes are able
to resist at least to some extent to autoimmune-mediated
demyelination (Ozawa et al. 1994). An important question
arises: which mechanisms lead to or protect from potential
harmful oligodendrocyte injury?
Oligodendrocytes - Lame Ducks?
Until now, many cell types have been shown to be
potentially able to damage oligodendrocytes. In the first
part of this review, we discuss some of these cell types and
their mediators leading to oligodendrocyte injury or death.
Figure 1 shows a schematic view of these cells and their
possible oligodendrocyte harming mediators.
Oligodendrocyte Injury Mediated by Immune Cells
In acute MS lesions, CD4+ and CD8+ T lymphocytes are
present. These cells can recognize their antigen if presented
by major histocompatibility complex (MHC) molecules
expressed on target cells, and be subsequently activated.
Under normal conditions, MHC expression in the CNS
does either not occur or is below detection levels (Redwine
et al. 2001). In vitro experiments showed, however, that
oligodendrocytes can be induced to express MHC class I
(Grenier et al. 1989; Kim 1985) and MHC class II
molecules (Bergsteindottir et al. 1992). Also in vivo, it
has been shown that oligodendrocytes are expressing MHC
class I molecules in a murine model of CNS inflammation
and demyelination (Redwine et al. 2001) and in MS lesions
(Hoftberger et al. 2004). This suggests that under patho-
logical conditions, oligodendrocytes induce MHC I expres-
sion and can thereby directly activate T cells and
consequently be damaged by them.
CD8+ T Lymphocytes
By the interaction of the CD8+ T cell receptor together with
the MHC class I peptide complex, CD8+ T cells are
activated and are directly cytotoxic to cells presenting their
specific antigen (Parkin and Cohen 2001). The activation of
CD8+ T cell by recognition of their specific antigen is then
followed by clonal expansion. In MS, this was shown by
analyzing lesions, blood, and cerebral spinal fluid (CSF) for
clonal composition and T cell receptor repertoire (Babbe
et al. 2000; Skulina et al. 2004). These results suggested
that CD8+ T cells might have recognized their specific
antigen within the lesion and might have been activated. It
Figure 1 Cells mediating oligodendrocyte injury in the course of MS.
Many different cell types have the potential to damage oligodendro-
cytes. In this figure, some of these cells and their potential
oligodendrocyte-damaging mediators are summarized. CD4+ Th1 T
cells have been shown to induce oligodendrocyte damage among
others through IL-2, LT, and IFN-g, whereas oligodendrocyte-
damaging mechanisms of Th17 T cells involve IL-6 and TNF-a.
CD8+ T cells can induce oligodendrocyte damage directly by MHC
class I-restricted cell lysis. Furthermore, g/δ T cells were also shown to
have the potential of damaging oligodendrocytes by direct lysis. By
secreting antibodies, B cell-mediated damage to oligodendrocytes
through opsonization was demonstrated. Macrophages are one of the
main cell types inducing oligodendrocyte damage by TNF-a, FasL,
ROS/RNS, and other mechanisms. Furthermore, astrocytes were
shown to be potentially harmful to oligodendrocytes by mechanisms
involving TNF-a, LT, and RNS
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has been shown that oligodendrocytes are susceptible to
cytolysis by CD8+ T lymphocytes (Jurewicz et al. 1998;
Ruijs et al. 1990). Furthermore, an involvement of CD8+
cytotoxic T lymphocytes in autoimmune demyelination was
shown in experimental autoimmune encephalomyelitis
(EAE) (Huseby et al. 2001; Sun et al. 2001). Altogether,
this suggests that CD8+ T lymphocytes might contribute to
oligodendrocyte injury in MS.
CD4+ T Lymphocytes
CD4+ T helper cells recognize their cognate antigen
exclusively in the context of MHC class II molecules. In
contrast to MHC class I molecules, the expression of MHC
class II molecules by oligodendrocytes could not be
demonstrated in MS (Lee and Raine 1989). MHC class II
expression is restricted to professional antigen-presenting
cells such as microglia/macrophages and dendritic cells
(Becher et al. 2000; Greter et al. 2005). It is easily
conceivable that CD4+ T helper cells induce oligodendrocyte
damage by secreting cytokines and promoting activation of
nearby macrophages and microglia. Studies in EAE suggest
that CD4+ T cells of the Th1 and Th17 lineage play a major
role in disease pathology (Gutcher et al. 2006; Langrish et al.
2005; Lassmann and Ransohoff 2004; Sospedra and Martin
2005; Weaver et al. 2006). Th1 cells are characterized by the
predominant secretion of IFN-g whereas Th17 cells are
shown to secrete IL-17A, IL-17F, and IL-22 (Iwakura and
Ishigame 2006; Kreymborg et al. 2007; McGeachy et al.
2007). It was shown that oligodendrocytes express TNF-a
receptors (Cannella et al. 2007; Raine et al. 1998) and other
cytokine receptors such as IFN-g receptor (Cannella and
Raine 2004), and treatment of oligodendroglial cell lines
with IFN-g induces apoptosis (Buntinx et al. 2004).
Oligodendrocytes were also shown to be susceptible to
TNF-a-induced cell death (D’Souza et al. 1996; Jurewicz
et al. 2005; Selmaj and Raine 1988). Taken together,
activated CD4+ T lymphocytes do contribute to some extent,
directly or indirectly, to oligodendrocyte injury in MS.
γ/δ T Lymphocytes
Another cell type found in MS lesions are g/δ T
lymphocytes (Wucherpfennig et al. 1992). g/δ T cells are
a T cell subpopulation showing a different T cell receptor
structure than a/β T cells (Li et al. 1998). The role of g/δ T
lymphocytes in MS is still unclear. Nevertheless, depletion
of g/δ T lymphocytes during EAE has been shown to
ameliorate disease severity during the acute phases of the
disease (Rajan et al. 1996). Furthermore, g/δ T cells were
shown to enhance adoptive transfer of EAE by promoting
antigen presentation and IL-12 production (Odyniec et al.
2004). As lysis of oligodendrocytes by g/δ T cells has been
demonstrated in vitro (Freedman et al. 1991), a possible
impact on oligodendrocyte injury in MS might not be ruled
out.
B Cells and Antibodies
In the CSF of MS patients, abnormal oligoclonal immuno-
globulin bands are detected, which supports the clinical
diagnosis of MS (Compston et al. 2006). Autoantibodies
against myelin components were reported to be present in
the serum, CSF, and lesions of MS patients (Genain et al.
1999; Reindl et al. 1999). In line with this, IgG isolated
from inflamed CNS tissue from MS patients were shown to
recognize MOG (O’Connor et al. 2005). Recently, menin-
geal B cell follicles were reported to associate with early
onset of disease and severe cortical pathology in secondary
progressive MS (Magliozzi et al. 2007). Therefore, anti-
body-producing B cells may have potential impact on
oligodendrocyte injury and demyelination. For example,
injection of antibodies augmented demyelination during the
course of a T cell-mediated transfer EAE (Linington et al.
1988). Further, it has been shown that by opsonizing the
myelin - oligodendrocyte surface, antibodies can stimulate
oligodendrocyte lysis of macrophages through their Fc
receptors (Scolding and Compston 1991). Also, another
demyelinating mechanism by antibodies was shown to
involve membrane attack complex (MAC) deposition,
which finally leads to complement-mediated cytolysis
(Mead et al. 2002; for review see Sospedra and Martin
2005). Altogether, direct antibody-mediated injury of
oligodendrocytes in MS might play an important role,
although its impact on MS pathogenesis could not be
determined yet.
Oligodendrocyte Injury Mediated by Activated
Macrophages/Microglia
Activated macrophages and microglia may play an impor-
tant role in inducing oligodendrocyte injury during acute
inflammation in MS. It has been shown that disease
severity in EAE correlates best with macrophage infiltration
(Berger et al. 1997). Activated macrophages and microglia
were shown to have incorporatedmyelin products and express
a large variety of different oligodendrocyte-deleterious com-
pounds, such as TNF-a, reactive oxygen species (ROS),
reactive nitrogen species (RNS), and Fas ligand (FasL).
TNF-a is a potent cytotoxic molecule capable of inducing
oligodendrocyte cell death (D’Souza et al. 1996; Jurewicz
et al. 2005; Selmaj and Raine 1988). The production of
ROS and RNS by activated macrophages and microglia
can lead to various types of damage such as lipid
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peroxidation, tyrosine nitrosylation, and DNA strand
breaks (van der Veen and Roberts 1999; Willenborg et al.
1999; Zhang et al. 1994). High expression of inducible
nitric oxide synthase (iNOS) and neuronal nitric oxide
synthase (nNOS) has been reported in activated macro-
phages and microglia within active lesions in MS (De
Groot et al. 1997; Hill et al. 2004), and RNS-mediated
damage in oligodendrocytes has also been demonstrated
(Jack et al. 2007; Li et al. 2005; Merrill et al. 1993).
Oligodendrocytes were also reported to express Fas in MS
lesions (D’Souza et al. 1996). FasL was shown to induce
oligodendrocyte damage (Li et al. 2002), and as microglia
express FasL in MS lesions (Becher et al. 1998), they
might, therefore, induce oligodendrocyte apoptosis. Fur-
thermore, it has been shown that activated macrophages
and microglia are capable of damaging oligodendrocytes in
an antibody-dependent mechanism (Griot-Wenk et al.
1991). Altogether, activated macrophages and microglia
might be one of the major mediators of oligodendrocyte
injury in MS.
Oligodendrocyte Injury Mediated by Astrocytes
Astrocytes are known to maintain physiological glutamate
levels in the brain. Therefore, malfunctioning or too slow
glutamate uptake might lead to an enhancement of oligo-
dendrocyte excitotoxic damage (Newcombe et al. 2007). In
addition, astrocytes are also known to express TNF-a and
LT-a. Thus, astrocytes might also be a potential inducer of
oligodendrocyte injury via TNF-a- and LT-a-dependent
mechanisms (for review see Williams et al. 2007). An
expression of all three isoforms of NOS by astrocytes was
also reported (for review see Gibson et al. 2005). In MS
plaques, high levels of constitutively expressed NOS were
detected to be expressed by astrocytes and macrophages
(De Groot et al. 1997). In contrast to astrocytes, oligoden-
drocytes are shown to be much more susceptible to NO-
induced oxidative stress (Mitrovic et al. 1995). This is
explained by the high iron load stored in oligodendrocytes
(Connor and Menzies 1995; Roskams and Connor, 1994;
Thorburne and Juurlink 1996) and their low content of
reduced glutathione (GSH) (Juurlink et al. 1998; Thorburne
and Juurlink 1996). Iron (Fe2+) was reported to be involved
in the formation of hydroxyl radicals (Gutteridge and
Halliwell 1989), whereas glutathione peroxidase activity,
using GSH as an electron donor, scavenges hydrogen
peroxide and thus inhibits hydroxyl radical formation
(Juurlink et al. 1998). A production of NO through NOS
expressed by astrocytes might, therefore, lead to oxidative
stress and damage in oligodendrocytes. Taken together,
activated astrocytes might also be involved in damaging
oligodendrocytes during the disease course of MS.
Reactive or Activated Oligodendrocytes - Pure Defensive
or Even Fierce Creatures?
As discussed before, immune cells and brain resident cells
are able to produce a variety of potentially harmful factors
for oligodendrocytes. These “attacks” are occurring either
directly via lysis or indirectly via toxic mediators or via an
imbalance of the surrounding environment. As demyelin-
ation is a major feature in MS and loss of oligodendrocyte
during the chronic disease process is also evident, oligo-
dendrocytes can be regarded as “poor victims” in the
pathogenic process of MS. Still, the question arises if
oligodendrocytes are really “lame ducks” passively allow-
ing disease progression or if they attempt to defend
themselves in one way or another, which could even
influence disease progression?
Studies characterizing oligodendrocytes in MS lesions, in
primary oligodendrocyte cultures, and in analysis of normal-
appearing white matter (NAWM) MS tissue, which is mostly
devoid of immune infiltrates - therefore suitable to study
prelesional activities of oligodendrocytes - have recently
disclosed a view of oligodendrocytes being potential
immune-modulating in MS. Furthermore, oligodendrocytes
were shown to successfully protect themselves during
pathogenesis of Balo’s concentric sclerosis (Stadelmann
et al. 2005). Altogether, these findings might lead to a view
of oligodendrocytes being at least capable to defend
themselves or even be a reactive - to some extent active
cell type - part of the immune privilege of the brain. In this
study, we discuss the capacity of oligodendrocytes to react
against certain insults for their own protection, and how they
might modulate their environment by influencing disease
progression.
Activation of Endogenous Protective Mechanisms
In the last few years, growing evidence suggest an involve-
ment of hypoxia-like pathogenic mechanisms in MS
(Lassmann 2003). Especially, in the so-called pattern III of
the lesion patterns identified recently (Lucchinetti et al.
2000), hypoxia-like tissue injury may play a pathogenetic
role (Aboul-Enein et al. 2003). Hypoxic tissue injury can be
induced in many ways. As already mentioned above, ROS
and RNS are known to induce cellular damages and
proposed to be involved in the demyelinating processes
(Smith et al. 1999). For example, NO can impair respiratory
chain function in mitochondria, and by that can cause axon
conduction block (Redford et al. 1997). In particular,
oligodendrocytes are vulnerable to NO-mediated damage
(Smith et al. 1999; Smith and Lassmann 2002), and
therefore, activation of mechanisms protecting oligodendro-
cytes from oxidative stress inducing damage would be highly
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beneficial. A recent study of subcortical NAWM from MS
cases has shown the upregulation of several genes involved
in ischemic preconditioning (Graumann et al. 2003). In
particular, HIF-1a has been shown to be an important
regulator of hypoxic preconditioning (Bergeron et al. 2000;
Bernaudin et al. 2002; Sharp et al. 2001) and is activated by
hypoxia, growth factors, NO, and others (for review see
Brune and Zhou 2007; Semenza 2002). HIF-1a and some of
its downstream genes were shown to be elevated in MS
NAWM (Graumann et al. 2003) and in situ hybridization
experiments of MS NAWM (Zeis et al. 2008), and
examinations of Balo’s concentric sclerosis identified oligo-
dendrocytes expressing this transcription factor (Stadelmann
et al. 2005), suggesting that oligodendrocytes mount
ischemic protective mechanisms during the disease course
(Fig. 2). Furthermore, oligodendrocytes were also shown to
express heat shock protein 70 (HSP70) (Stadelmann et al.
2005) and HSP32 (Stahnke et al. 2007). In the case of
HSP70, a protective role has been shown in brain ischemia
(for review see Christians et al. 2002), whereas HSP32 was
shown to exert a protective role against oxidative stress in an
oligodendroglial cell line (Stahnke et al. 2007).
It is interesting to note that sublethal doses of inflam-
matory cytokines such as IFN-g and TNF-a were reported
to induce protective mechanisms in target cells (Fig. 2). The
induction of HSP70 in oligodendrocytes was shown in vitro
by treatment of oligodendrocyte cultures with a mix of
cytokines (D’Souza et al. 1994). Furthermore, treatment of
oligodendrocyte cultures with IFN-g led to an increase in
the expression of genes involved in protection against
oxidative stress (Balabanov et al. 2007). In line with this,
treatment of mice with IFN-g before the onset of EAE led
to an amelioration of the disease through activating the
integrated stress response (Lin et al. 2007). Altogether,
oligodendrocytes are able to induce and express endoge-
nous protective mechanisms allowing them to survive in an
otherwise potentially lethal environment.
Growth Factors
Changes in growth factors and growth factor receptors
expression were demonstrated in MS. Several growth
factors such as nerve growth factor (NGF), insulin-like
growth factor (IGF), and transforming growth factor β
(TGF-β) were reported to be expressed by oligodendro-
cytes (for review see Du and Dreyfus 2002). By expression
of these factors, oligodendrocytes might influence the
survival and/or function of neighboring cells. NGF can
bind to the tyrosine kinase receptor A (TrkA) and to the
low-affinity nerve growth factor receptor (p75NTR). By
binding to TrkA, NGF promotes cell survival whereas
binding to p75NTR under some circumstances might also
modulate susceptibility to programmed cell death or
apoptosis (Casaccia-Bonnefil et al. 1999; Yoon et al.
1998). In EAE, the expression of TrkA was detected on
neurons, astrocytes, and oligodendrocytes (Oderfeld-
Nowak et al. 2003; Oderfeld-Nowak et al. 2001), whereas
p75NTR was detected on neurons, microglia, astrocytes, and
oligodendrocytes (Nataf et al. 1998; Villoslada et al. 2000).
In EAE, NGF was shown to have beneficial effects, as
NGF-deprived rats display more severe neurological defi-
cits during disease course. Furthermore, treatment of
marmoset monkeys with NGF prevented the full develop-
ment of EAE lesions and delayed the onset of clinical EAE
(Micera et al. 2000; Villoslada et al. 2000). Another growth
factor expressed by oligodendrocytes is IGF-1, which was
reported to ameliorate TNF-a-induced demyelination in
transgenic mice (Ye et al. 2007). Furthermore, IGF-1 was
also reported to reduce demyelination in EAE (Liu et al.
1995), although this beneficial effect is still under debate
(Cannella et al. 2000). The expression of TGF-β by
oligodendrocytes was also reported, which is discussed in
the next chapter. Altogether, by expressing several growth
factors, oligodendrocytes are able to influence their own
function and survival, and also the function and survival of
nearby cells.
Figure 2 Ischemic preconditioning pathways in oligodendrocytes.
Recent studies showed that oligodendrocytes can mount ischemic
preconditioning mechanisms upon different stimuli. Treatment of
oligodendrocytes with sublethal doses of IFN-g and TNF-a led to the
upregulation of genes involved in ischemic tolerance. Protective genes
were also shown to be upregulated in oligodendrocytes after
stimulation with growth factors. Furthermore, low levels of RNS/
ROS were reported to lead to a stabilization of HIF-1a, which in turn
activates the transcription of protective genes such as for example
VEGFR, GLUT1, and GLUT3
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Potential Immune-modulating Ability
of Oligodendrocytes
Immunohistochemical analysis of proteins expressed by
oligodendrocytes revealed that oligodendrocytes are able to
express cytokine receptors and members from the JAK/
STAT family (Cannella and Raine 2004; Zeis et al. 2008).
In a recent study, we have shown that genes from the
STAT6 signaling pathway are upregulated in MS NAWM
and that STAT6 and its members JAK1/3, IL-4R, and IL-
13R are expressed by oligodendrocytes (Figs. 3 and 4)
(Zeis et al. 2008). The STAT6 signaling pathway is known
from CD4+ T helper cells type 2, and it has been shown that
STAT6 is critically required for differentiation into Th2
cells (Kaplan et al. 1996). Although still debated, cytokines
of the Th2 type such as IL-4 and IL-10 are thought to be
mostly beneficial in MS and EAE (Cannella and Raine
2004; Sospedra and Martin 2005). In EAE, it has been
shown that STAT6 knockout mice develop a more severe
disease than wild-type mice (Chitnis et al. 2001). This
might be because of the lack of Th2 cells and of the
inability of oligodendrocytes to modulate their environment
in an anti-inflammatory way. The expression and activation
of an anti-inflammatory response by oligodendrocytes
might be crucial for them to compensate for the upregulated
proinflammatory environment and to limit the inflammatory
response and damage (Zeis et al. 2008). The expression of
different cytokine receptors on oligodendrocytes in active
and silent lesions may further suggest an active role in
innate immunity of the CNS (Cannella and Raine 2004).
Oligodendrocytes were also shown to express TGF-β in
vitro (da Cunha et al. 1993; McKinnon et al. 1993), which
can suppress immune and inflammatory responses (for
review see Pratt and McPherson 1997), and might promote
myelination and remyelination (Setzu et al. 2006).
In vitro experiments suggested that, upon stimulation by
INF-γ, oligodendrocytes express protective genes against
oxidative stress and a number of chemokines, including
CXCL10, CCL2, CCL3, and CCL5 (Fig. 4) (Balabanov
et al. 2007). CXCL10, CCL2, and CCL5 were also found to
be upregulated in MS NAWM (Graumann et al. 2003).
Furthermore, mice with oligodendrocytes with suppressed
responsiveness to IFN-g showed higher oligodendrocyte
apoptosis in EAE and an accelerated disease onset, but
milder perivascular inflammation and minimal parenchymal
infiltration and demyelination (Balabanov et al. 2007). This
effect of IFN-g on oligodendrocytes demonstrates that
oligodendrocytes are capable to react on external immune
Figure 3 STAT6 signaling pathway expression in oligodendrocytes.
Recently, oligodendrocytes were shown to be able to express immune
mechanism relevant genes. Immunofluorescence colocalization anal-
ysis of proteins from the STAT6 signaling pathway in MS patients
revealed the expression of IL-4R (a), IL-13R (b), and STAT6 (c) in
oligodendrocytes (Olig2 positive) in subcortical normal-appearing
white matter brain tissue. a Colocalization of STAT6 (red), IL-4R
(green, inset), OLIG2 (blue), and DAPI (cyan); b colocalization of
STAT6 (red), IL-13R (green, inset), OLIG2 (blue), and DAPI (cyan);
c colocalization of STAT6 (red), OLIG2 (blue), and DAPI (cyan) in
oligodendrocytes arranged in interfascicular rows, which is typical for
myelinating oligodendrocytes (for more detailed pictures see Zeis
et al. 2008). Scale bar=25 μm
Figure 4 Immune response-mediating pathways in oligodendrocytes.
Analysis of proteins expressed by oligodendrocytes revealed that
oligodendrocytes are able to express immune mechanisms-related
proteins. Members of the STAT6 signaling pathway, such as IL-4R,
IL13R, JAK1, and STAT6, were shown to be expressed by
oligodendrocytes. This might indicate an anti-inflammatory “Th-2”-
like response by oligodendrocytes. Furthermore, treatment of oligo-
dendrocytes with a sublethal dose of IFN-g and TNF-a led to the
secretion of chemokines such as CXCL10 (IP-10), CCL2 (MCP-1),
CCL3 (MIP-1a), and CCL5 (Rantes). Altogether, this indicates that
oligodendrocytes might play an immune-modulating role MS
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challenges by induction of protective mechanisms and that
they can modulate inflammatory responses. The expres-
sion of cytokine receptors and members from the anti-
inflammatory STAT6 signaling pathway and the possibility
of chemokine expression might point to oligodendrocytes
playing a role in the innate immunity by actively modulating
their environment and interacting with cells of the immune
system.
Conclusions
Oligodendrocytes as the myelinating cell type in the CNS
are the major targets in MS. Many studies have shown that
oligodendrocytes are easily damaged by various mecha-
nisms. Therefore, oligodendrocytes might be seen as “lame
ducks” of the CNS. However, growing evidence indicate
that oligodendrocyte are far more than a passive presence in
the CNS during MS. Oligodendrocytes are either constitu-
tively expressing or inducing various molecules able to
influence inflammatory reactions and prevent cell death to
conserve the functionality of the CNS. It seems that
oligodendrocytes in MS have a rather active or reactive
phenotype, preventing fatal damage and modulating their
surrounding. Therefore, oligodendrocytes may even act as
“fierce creatures,” influencing innate immunity and being
an active part in the formation of the immune privilege of
the brain.
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